Ley v. Collins

Court of Appeals for the Federal Circuit·Decided August 7, 2026·No. 25-1425·Published

Opinion

United States Court of Appeals for the Federal Circuit

RICHARD J. LEY, Claimant-Appellant

v.

DOUGLAS A. COLLINS, SECRETARY OF VETERANS AFFAIRS, Respondent-Appellee

2025-1425

Appeal from the United States Court of Appeals for Veterans Claims in No. 23-1547, Chief Judge Michael P. Allen, Judge Grant Jaquith, Judge Joseph L. Falvey, Jr.

Decided: August 7, 2026

HAROLD HAMILTON HOFFMAN, III, Veterans Legal Advocacy Group, Arlington, VA, for claimant-appellant. Also represented by JENNIFER TRACY SHANNON HEALY.

MATTHEW JUDE CARHART, Commercial Litigation Branch, Civil Division, United States Department of Justice , Washington, DC, for respondent-appellee. Also represented by WILLIAM JAMES GRIMALDI, PATRICIA M. MCCARTHY, BRETT SHUMATE; MATTHEW ALBANESE, BRIAN D. GRIFFIN, Office of General Counsel, United States Department of Veterans Affairs, Washington, DC.

2 LEY v. COLLINS

Before MOORE, Chief Judge, PROST and CUNNINGHAM, Circuit Judges.

MOORE, Chief Judge.

Richard J. Ley appeals a decision of the United States Court of Appeals for Veterans Claims (Veterans Court) affirming the Board of Veterans’ Appeals (Board) denial of an earlier effective date for his service-connected chronic lymphocytic leukemia (CLL). For the following reasons, we affirm the Veterans Court decision.

BACKGROUND Mr. Ley served honorably in the United States Marine Corps from October 1962 to December 1966, including a tour in Vietnam. J.A. 3; J.A. 38. After he reported consistent fatigue, a 2010 check-up at a Veterans Affairs Medical Center (VAMC) in Florida indicated Mr. Ley had an absolute lymph count (ALC) of 5,200. J.A. 3; J.A. 124–25. The Department of Veterans Affairs (VA) doctor determined Mr. Ley did not meet the criteria for CLL and instead diagnosed Mr. Ley with monoclonal B-cell lymphocytosis (MBL). J.A. 125–26. After his symptoms worsened, Mr. Ley was referred to a VA hematologist who confirmed his MBL diagnosis in 2012. J.A. 3–4; J.A. 127. The hematologist noted Mr. Ley’s ALC had exceeded 5,000 since 2010 but showed clonal levels “less than [the] official criteria of 5[,]000 for CLL.” J.A. 127. The hematologist specifically noted he “did not use the term leukemia” with Mr. Ley, informing him only that he had MBL and may “need further investigation” in twenty years. Id.

Mr. Ley continued receiving annual check-ups, but his condition worsened, ultimately leading to the loss of employment and the sale of his home. J.A. 4–5. After moving from Florida to Tennessee, Mr. Ley sought care at a new VAMC facility where a VA oncologist diagnosed him with

LEY v. COLLINS 3

CLL, presumptively resulting from Agent Orange exposure during his service in Vietnam. J.A. 5; J.A. 122; J.A. 1617. The VA oncologist later determined Mr. Ley had CLL since 2010, because the 2010 pathology report both showed an ALC of “5,200” and properly noted “the diagnostic criterion ” for CLL was a level “greater than 5,000 monoclonal lymphocytes.” J.A. 123.

Four days after receiving his CLL diagnosis, Mr. Ley applied for disability compensation. J.A. 2479–82; see J.A. 122. The VA regional office awarded him a 100% disability rating with an effective date of January 29, 2016— the date the VA received his claim. J.A. 5; J.A. 2003–05. Mr. Ley appealed, requesting an earlier effective date because he met the criteria for CLL in 2010 and the Florida VA doctors allegedly misdiagnosed him, failed to inform him he had CLL, or both. J.A. 5–6; J.A. 496–502. The Board ultimately granted Mr. Ley an effective date of January 29, 2015, but no earlier. J.A. 105. The Board acknowledged Mr. Ley’s “assertion that VA’s failure to properly inform him of his CLL diagnosis prevented him from filing an earlier disability compensation claim” but determined “the law does not permit VA to take such factors into account when assigning an effective date” under 38 U.S.C. § 5110. J.A. 109.

Mr. Ley appealed the Board’s decision arguing only (1) the VA was equitably estopped from enforcing the effective date limitations of 38 U.S.C. § 5110, and (2) 38 U.S.C. § 5110’s limitations were unconstitutional as applied to Mr. Ley. J.A. 2. The Veterans Court affirmed the Board’s decision. Mr. Ley timely appeals. We have jurisdiction under 38 U.S.C. § 7292.

DISCUSSION Our jurisdiction to review decisions of the Veterans Court is limited. Wanless v. Shinseki, 618 F.3d 1333, 1336 (Fed. Cir. 2010). We may review “all relevant questions of law, including interpreting constitutional and statutory 4 LEY v. COLLINS

provisions.” 38 U.S.C. § 7292(d)(1). Except with respect to constitutional issues, we “may not review (A) a challenge to a factual determination, or (B) a challenge to a law or regulation as applied to the facts of a particular case.” Id. § 7292(d)(2).

On appeal, Mr. Ley raises two challenges to the Veterans Court decision. First, he argues the Veterans Court erred in determining equitable estoppel was foreclosed by our decision in Taylor v. McDonough, 71 F.4th 909 (Fed. Cir. 2023). Second, he argues the Veterans Court erred in holding 38 U.S.C. § 5110’s effective date limitations were not unconstitutional as applied to him.

I

“We review the Veterans Court’s legal interpretations de novo.” Beaudette v. McDonough, 93 F.4th 1361, 1366 (Fed. Cir. 2024) (citation omitted). Mr. Ley argues the Veterans Court misinterpreted Taylor when holding it foreclosed the use of equitable estoppel to override 38 U.S.C. § 5110’s limitations. First, Mr. Ley argues Taylor was only a plurality opinion and thus nonbinding on the Veterans Court. Second, Mr. Ley argues he is nonetheless entitled to equitable estoppel because the VA violated its statutory duty under 38 U.S.C. § 7331 to inform him he had CLL.

A

Mr. Ley’s first argument, that Taylor is nonbinding, misinterprets our decision. Our opinion in Taylor makes clear that Parts I–IV, joined by eight of the thirteen judges sitting en banc, “constitute an opinion for the court.” 71 F.4th at 915. The Veterans Court correctly relied upon these parts of Taylor, id. at 925–28, which are binding precedent .

B

Mr. Ley argues he is nonetheless entitled to equitable estoppel because the VA violated its statutory duty under

LEY v. COLLINS 5

38 U.S.C. § 7331 to inform him he had CLL. In Taylor, the majority held that “equitable estoppel is not available to override the claim-filing effective-date limits of § 5110.” 71 F.4th at 927–28. We acknowledged, however, that if a statute establishes a duty the VA must comply with as a precondition to enforcing the limitations of 38 U.S.C. § 5110, and that “precondition provision [is] violated,” then enforcing those limitations “would be contrary to statute.” Id. at 928–29. In such scenarios, the veteran should receive “what would have been paid had there been no precondition -provision violation.” Id. at 929. We made clear that “[t]he basis for such an award is not the doctrine of equitable estoppel” but rather “a statutory-violation and remedy analysis.” Id. (emphasis added).

Mr. Ley argues he is entitled to equitable estoppel because the VA, through the Florida VA doctors, violated its statutory duty under 38 U.S.C. § 7331 to inform him of his CLL diagnosis, and this statutory duty is a precondition to enforcing the effective date limitations of 38 U.S.C. § 5110. In so arguing, Mr. Ley improperly relies on the concurrence in Taylor, not the proper framework set forth by the majority , which held that “equitable estoppel is not available to override the claim-filing effective-date limits of § 5110.” 71 F.4th at 927–28. Moreover, even assuming Mr. Ley’s argument was properly preserved 1 and presented under the correct framework, 38 U.S.C. § 7331 does not create a

Free access — add to your briefcase to read the full text and ask questions with AI

Ley v. Collins, (Fed. Cir. 2026).

Ley v. Collins (Ley v. Collins) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Wanless v. Shinseki
618 F.3d 1333 (Federal Circuit, 2010)
Taylor v. McDonough
71 F.4th 909 (Federal Circuit, 2023)
Beaudette v. McDonough
93 F.4th 1361 (Federal Circuit, 2024)